Exciting Presentation by Lantheus at Goldman Sachs Healthcare Conference
BEDFORD, Mass. — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH) is known for its significant contributions to the field of radiopharmaceuticals. As part of its commitment to innovating patient care, Lantheus announced that Brian Markison, the Chief Executive Officer, will deliver a presentation at the prestigious Goldman Sachs 46th Annual Global Healthcare Conference. This event is set to take place at 2:40 p.m. ET on a Tuesday in June.
What to Expect from the Presentation
During this anticipated presentation, attendees can expect insightful discussions focused on Lantheus' advancements in the production and application of radiopharmaceuticals. These innovations are vital for enabling clinicians to effectively identify, combat, and track diseases, ultimately aiming to enhance patient outcomes. Lantheus has steadily been at the forefront of integrating advanced radiopharmaceutical technologies into standard medical practices.
Accessing the Live Webcast
For those who cannot attend in person, a live webcast of the presentation will be accessible. Individuals interested in following along can visit the Investors section of the ?antheus Company website. This digital platform ensures that stakeholders and the public can stay informed about Lantheus' strategic initiatives and corporate developments. Furthermore, a replay of the presentation will be available on the company’s website for at least 30 days, allowing for greater accessibility to this important event.
About Lantheus Holdings, Inc.
Lantheus stands as a pivotal player in the radiopharmaceutical industry, delivering groundbreaking solutions that assist healthcare providers in diagnosing and treating diseases. With nearly 70 years of experience, Lantheus is dedicated to enhancing patient care through scientifically advanced radiopharmaceuticals. Although headquartered in Massachusetts, the company's influence extends beyond borders, with offices also in New Jersey, Canada, and Sweden.
Mission and Vision of Lantheus
The mission of Lantheus is clear: to deliver life-changing scientific advancements that allow practitioners to Find, Fight, and Follow diseases more effectively. This clear focus aligns with their vision of pioneering diagnostic and therapeutic methods that can significantly improve the quality of care patients receive, ultimately enhancing survival and improving life quality.
Contacts for More Information
For inquiries, Lantheus offers dedicated contact points to assist stakeholders and media. Mark Kinarney serves as the Vice President of Investor Relations at Lantheus and can be reached at 978-671-8842 for investor-related queries. Melissa Downs, the Executive Director of External Communications, is also available at 646-975-2533 for media inquiries. Both contacts are instrumental in facilitating communication and providing further information about the company's initiatives.
Frequently Asked Questions
What is Lantheus known for?
Lantheus is renowned for its expertise in radiopharmaceuticals, enhancing disease detection and treatment.
Where will the presentation be held?
The presentation will take place at the Goldman Sachs Annual Global Healthcare Conference.
How can I access the webcast of the presentation?
You can access the live webcast through the Investors section of the Lantheus website.
Who is presenting on behalf of Lantheus?
Brian Markison, the Chief Executive Officer of Lantheus, will represent the company during the conference.
How long has Lantheus been in business?
Lantheus has been operational for nearly 70 years, making a substantial impact in the field of radiopharmaceuticals.
